1
Jul 24
Pfizer ordered to pay damages to the National Health System for abusing a dominant position in managing the Xalatan patent lifecycle
From 2012 to 2014, Pfizer Italia S.r.l., Pfizer Health A.B., and Pfizer Inc. and Ratiopharm Italia S.r.l. locked horns in litigation before the AGCM and the Italian administrative court.
29
May 24
Bolar exemption, UPCA and Pharma Package: What to expect? An Italian perspective
This article has been first published on April 29, 2024 on the International Bar Association (IBA)'s newsletter.
20
Jun 23
European Commission proposals for new regulation of compulsory licensing
On April 27, 2023, the European Commission published proposals for a new set of regulations aimed at establishing a more transparent and effective framework for patent rights.
27
Jan 23
Patent monopolies and the pandemic emergency: Obstacle or opportunity?
The outbreak of the Covid-19 pandemic generated extensive debate regarding equitable access to vaccines and medical treatments. In this framework, discussion of the role of patents in health care came to the fore: Are patents a resource, or are they instead an obstacle to the widespread protection of public health during a pandemic emergency?
15
Apr 21
Pay-for-delay: The Court of Justice clarifies the scope of “by object” restrictions and “potential competition” in patent settlement cases
On March 25, 2021, the Court of Justice of the European Union ruled on appeal in the Lundbeck case, confirming the previous judgement of the General Court that upheld the decision of the European Commission on pharmaceutical “pay-for-delay” agreements.
20
Jul 20
Supplementary protection certificates and Court of Justice: clarifications on the conditions for obtaining a supplementary protection certificate
On July 9, 2020, the Court of Justice (the “Court”) ruled on supplementary protection certificates (“SPCs”) in case C-673/18.
